Salute e Benessere

Manchester charity recognises UK hero volunteers

Human Appeal’s Purple Legacy Awards returned for the second year Purple Legacy Awards 2025, that recentlytook place. The first was organised in 2024 to celebrate the selfless work of the charity’s network of volunteers nationwide.With 16 awards categories on the evening, thePurple Legacy Awardstakes inspiration from the charity’s purple logo and motto, ‘here for every human’. The idea of legacy is at the heart of the ceremony and Human Appeal’s work transforming lives at home and...
Nasdaq GlobeNewswire
16/09/2025

New Scientific Review Highlights β-Lactoglobulin's Dual Benefits for Metabolic…

BLG's dual benefits BLG's dual benefits Rich in leucine and capable of generating bioactive peptides during digestion, BLG offers a rare combination of metabolic and muscle-preserving benefits – two of the most pressing nutrition challenges in ageing and metabolic health. The review highlights several features that set BLG apart. It contains 1.5 times more leucine than standard whey or casein, providing a strong trigger for muscle protein synthesis. BLG ensures sustained amino acid...
PR Newswire
16/09/2025

Trident Group Deepens MENA Footprint with AED 6 million Investment at Sleep Expo…

At Sleep Expo ME 2025, held from 15-17 September at Sheikh Saeed Hall 1–3 & Trade Centre Arena, Dubai World Trade Centre, Trident showcased its full range including Bed & Bath Linen, My Trident, Yarn, Paper, and Bathrobes. Sleep Expo Middle East is MENA's largest and most influential event dedicated to the sleep, mattress, and bedding industry. The central theme of the showcase was the 20th anniversary of Trident's patented Air Rich® technology, a pioneering textile innovation inspired…
PR Newswire
16/09/2025

New Study Finds Pycnogenol® Alleviates Cellulite in Women

Published in Phytomedicine Plus, the study evaluated 60 women aged 25 to 45 years over the course of three months, with cellulite status and response measured at baseline, 4 weeks, 8 weeks, and 12 weeks. Thirty (30) women took 150 mg of Pycnogenol® a day (50 mg in the morning and 100 mg in the evening), while thirty (30) women took a placebo. Key findings include: Published in Phytomedicine Plus , the study evaluated 60 women aged 25 to 45 years over the course of three months, with...
PR Newswire
16/09/2025

Cantoni Therapeutics secures financing to advance novel non-incretin obesity…

Brabant Development Agency (BOM) and angel investor join lead investor Libertatis Ergo Holding (LEH) in providing funding, with additional financial support from Brabant Startup Fund (BSF)Cantoni awarded validatioNN grant from Novo Nordisk to support disease-relevant translational research on NNMT, a novel target for cardiometabolic diseases, including obesity and its comorbiditiesOSS, Netherlands, September 16, 2025 - Cantoni Therapeutics B.V. (‘Cantoni’), a biotech company spun...
Nasdaq GlobeNewswire
16/09/2025

Basilea receives USD 25 million funding under BARDA agreement to continue to…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services,...
Nasdaq GlobeNewswire
16/09/2025

MAGIC IS ON ITS WAY WITH SELFRIDGES AND DISNEY

'A Most Magical Christmas' is inspired by timeless Disney stories and characters, bringing a sense of nostalgia and playfulness to a series of extraordinary and unforgettable in-store and online experiences. Visitors are invited to embrace the joys of childhood, immersing themselves in an expression of the timeless Disney adage "You're never too old to be young". 'A Most Magical Christmas' is inspired by timeless Disney stories and characters, bringing a sense of nostalgia and…
PR Newswire
16/09/2025

People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted…

Results from a real-world survey suggest that semaglutide for weight management (Wegovy ® ) helped suppress food noise – unwanted and intrusive thoughts about food – in addition to its established effect on weight loss 1 The number of people who reported experiencing constant thoughts about food throughout the day declined by 46% after starting treatment with Wegovy ®1 The majority of respondents reported improved mental health (64%) and healthier habits (80%) while taking Wegovy ®1 ...
Nasdaq GlobeNewswire
16/09/2025

Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade…

Bispecific Antibodies in Oncology Market Summary Bispecific Antibodies in Oncology Market Summary Discover which indication is expected to grab the major bispecific antibodies in oncology market share @Bispecific Antibodies in Oncology Market Report Key Factors Driving the Growth of the Bispecific Antibodies in Oncology Market Rising Cancer Incidence The increasing global prevalence of cancer is a significant driver for the bispecific antibodies market. The WHO/IARC...
PR Newswire
15/09/2025

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc. (collectively, “Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that it has filed a lawsuit against Inspire Medical Systems, Inc. (“Inspire”) alleging that the Inspire...
Nasdaq GlobeNewswire
15/09/2025

Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates…

PAINWeek is a prestigious event that brings together thousands of leading clinicians, researchers, educators, and potential pharmaceutical partners in the field of pain medicine, offering a rare chance to connect, share ideas, and highlight new approaches. At the conference, Dr. Pergolizzi presented data from a narrative review highlighting the limitations of plant-derived CBD oils in treating chronic pain and the urgent need for regulated, long-acting synthetic CBD therapies. In parallel…
PR Newswire
15/09/2025

LBB Specialties and Imerys Form Specialty Distribution Partnership in North…

This partnership enhances LBBS's portfolio, expanding access to innovative, sustainability-driven mineral technologies. By combining Imerys' globally recognized expertise in mineral science with LBBS's market reach and customer support, the collaboration strengthens resources for formulators facing complex technical and regulatory challenges. This partnership enhances LBBS's portfolio, expanding access to innovative, sustainability-driven mineral technologies. By combining Imerys' globally...
PR Newswire
15/09/2025

Diphtheria Tetanus Pertussis (DTP) Vaccine Market Driven by Rising Immunization…

The expansion is largely attributed to increasing vaccination rates, supportive healthcare policies, and technological advancements in vaccine production, highlighting the market's critical role in global immunization efforts and disease prevention strategies. The expansion is largely attributed to increasing vaccination rates, supportive healthcare policies, and technological advancements in vaccine production, highlighting the market's critical role in global immunization efforts and…
PR Newswire
15/09/2025

Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST…

SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEMGhent, Belgium, 15 September 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a subscription request notice in accordance with the terms of the share subscription facility…
Nasdaq GlobeNewswire
15/09/2025

Guerbet : Adjustment of 2025 full-year financial targets

Adjustment of 2025 full-year financial targets Villepinte, 15 September 2025, 5.45 p.m.:Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to its financial targets for full-year 2025.Business activity in France continues to be impacted by supply reforms. In the United States, an unfavourable shift in the customer mix, with distributors representing a higher proportion...
Nasdaq GlobeNewswire
15/09/2025

Cancer Gene Therapy Market Size Worth US$ 19.97 Billion by 2033, with a 19.8%…

Furthermore, the market is experiencing significant growth due to increased research and development activities, advancements in product technologies, and the introduction of new products by key industry players. This progress is propelling the healthcare infrastructure to unprecedented levels. For instance, in April 2023, an improved gene editing method was introduced based on special cell-penetrating peptides, representing a significant advancement in cell and gene therapies. This technique…
PR Newswire
15/09/2025

Neuromodulation Market worth US$10.68 billion by 2030 with 9.4% CAGR |…

Browse in-depth TOC on "Neuromodulation Market" Browse in-depth TOC on "Neuromodulation Market" 400 - Tables 45 - Figures 350 - Pages By technology,the neuromodulation technology market is categorized into two main types: internal neuromodulation and external neuromodulation. The internal neuromodulation segment held the largest market share in 2024. Internal neuromodulation has an advantage due to its ability to deliver targeted, long-term therapy for chronic…
PR Newswire
15/09/2025

Immunohistochemistry Market worth US$5.14 billion by 2030 with 7.6% CAGR |…

Browse in-depth TOC on "Immunohistochemistry Market" Browse in-depth TOC on "Immunohistochemistry Market" 666 - Tables 63 - Figures 490 - Pages By offering,the immunohistochemistry market is segmented into antibodies, reagents, kits, equipment, and software. Kits were the fastest-growing segment during the forecast period 2025-2030. This surge is driven by a significant market shift among end-users, including high-volume diagnostic laboratories, hospitals, and research...
PR Newswire
15/09/2025

Pediatric Clinical Trials Market Size Worth US$ 31.77 Billion by 2033, with a…

Nirsevimab (Beyfortus) is a breakthrough monoclonal antibody approved to prevent Respiratory Syncytial Virus (RSV) in infants and young children, providing protection throughout the RSV season with a single injection. Clinical trials demonstrated a 70-75% reduction in RSV-related hospitalizations among preterm and term infants. Beyfortus exemplifies how pediatric trials are delivering life-saving therapies. Nirsevimab (Beyfortus) is a breakthrough monoclonal antibody approved to prevent...
PR Newswire
15/09/2025

Diagnostic Imaging Market worth US$32.90 billion by 2030 with 4.4% CAGR |…

Browse in-depth TOC on "Diagnostic Imaging Market" Browse in-depth TOC on "Diagnostic Imaging Market" 399 - Tables 55 - Figures 393 - Pages By product,the global diagnostic imaging market is divided into several segments: CT scanners, X-ray imaging systems, ultrasound systems, MRI systems, nuclear imaging systems, and mammography systems. The MRI systems segment is expected to register the highest growth rate during the forecast period. The demand for enhanced MRI scans is...
PR Newswire
15/09/2025

Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for…

Approval Highlights CP-9's Safety and Quality Approval Highlights CP-9's Safety and Quality According to the FDA filing, CP-9 is authorized for use at levels up to 10⁹ colony-forming units (CFUs) per-serving in a wide range of food and beverage products: The newly approved CP-9 was a finalist at the 2023 NutraIngredients Awards and has been studied for its role in gut health and immune regulation. With FDA GRAS status, CP-9 expands Glac Biotech's portfolio and is expected to serve the...
PR Newswire
15/09/2025

LabConnect and OmniScience to Deliver First Agentic AI Solution for Real-Time…

Faster Decisions and Smarter Oversight with LabConnect + Vivo Clinical trial lab data is often siloed, complex, and delayed. This causes slow decision-making and introduces risk. By combining LabConnect's expertise in central lab testing and data management with OmniScience's Vivo platform, trial sponsors can now unify fragmented lab datasets, automate oversight, and surface risk signals that accelerate trial timelines and improve outcomes. Faster Decisions and Smarter Oversight with...
PR Newswire
15/09/2025

Conceivable Life Sciences Secures $50 Million Series A

Funding supports U.S. market launch of AURA, World’s first AI-powered automated IVF lab NEW YORK, Sept.15, 2025(GLOBE NEWSWIRE) -- Conceivable Life Sciences today announced its $50 million Series A financing to accelerate the development and commercialization of the world's first AI-powered automated IVF laboratory. The funding will support the company's mission to make this Nobel Prize-winning therapy more accessible, scalable, and effective at delivering improved pregnancy results...
Nasdaq GlobeNewswire
15/09/2025

Kolmar Korea Advances 'Clean Beauty' with Breakthroughs from Eco-Friendly…

These innovations have earned international recognition. The paper tube and paper stick achieved a "grand slam" in design by winning the world's top three design awards—IDEA, iF Design Award, and Red Dot Design Award. The one-hand pump paper pack also won a Red Dot Design Award this year, further validating the global competitiveness of Kolmar Korea's eco-friendly packaging. These innovations have earned international recognition. The paper tube and paper stick achieved a "grand…
PR Newswire
15/09/2025
Altri  Comunicati